within Pharmacolibrary.Drugs.ATC.L;

model L01XD04
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.6,
    Cl             = 2.166666666666667e-06,
    adminDuration  = 600,
    adminMass      = 20 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00039,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0035,
    Tlag           = 10.200000000000001
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01XD04</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Aminolevulinic acid (ALA) is a natural precursor in the heme biosynthesis pathway and is used as a photosensitizing agent in photodynamic therapy, particularly for the treatment of actinic keratosis, superficial basal cell carcinoma, and as an adjunct in tumor imaging. It is approved for topical and oral use in some countries but its use as an anticancer agent is under continued investigation.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters for orally administered aminolevulinic acid in healthy adult volunteers.</p><h4>References</h4><ol><li><p>Dalton, JT, et al., &amp; Golub, AL (1999). Pharmacokinetics of aminolevulinic acid after oral and intravenous administration in dogs. <i>Drug metabolism and disposition: the biological fate of chemicals</i> 27(4) 432–435. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/10232930/\">https://pubmed.ncbi.nlm.nih.gov/10232930</a></p></li><li><p>Rick, K, et al., &amp; Baumgartner, R (1997). Pharmacokinetics of 5-aminolevulinic acid-induced protoporphyrin IX in skin and blood. <i>Journal of photochemistry and photobiology. B, Biology</i> 40(3) 313–319. DOI:<a href=\"https://doi.org/10.1016/s1011-1344(97)00076-6\">10.1016/s1011-1344(97)00076-6</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/9372622/\">https://pubmed.ncbi.nlm.nih.gov/9372622</a></p></li><li><p>Yadav, V, et al., &amp; Basit, AW (2021). 5-Aminolevulinic Acid as a Novel Therapeutic for Inflammatory Bowel Disease. <i>Biomedicines</i> 9(5) –. DOI:<a href=\"https://doi.org/10.3390/biomedicines9050578\">10.3390/biomedicines9050578</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34065300/\">https://pubmed.ncbi.nlm.nih.gov/34065300</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01XD04;
